Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors

NCT00104676 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00104676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
November 26, 2003
Completion date
February 8, 2023
Enrollment
263 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

extragonadal germ cell tumor, teratoma, testicular germ cell tumor